EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSGACG00000012122
Gene Symbol: MAP3K9
1 Cross references
195 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSGACG00000005782
Gene Symbol: MGLL
1 Cross references
208 Possible Orthologues:

Natriuretic Peptide Receptor 1a

Ensembl ID : ENSGACG00000010362
Gene Symbol: NPR1A
1 Cross references
194 Possible Orthologues:

Natriuretic Peptide Receptor 2

Ensembl ID : ENSGACG00000000923
Gene Symbol: NPR2
1 Cross references
191 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSGACG00000003906
Gene Symbol: NPR3
1 Cross references
210 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSGACG00000004431
Gene Symbol: NTSR1
2 Cross references
199 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSGACG00000007625
Gene Symbol: NTRK2
1 Cross references
208 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSGACG00000002033
Gene Symbol: NTRK3
2 Cross references
183 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSGACG00000014782
Gene Symbol: NTRK3
1 Cross references
203 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 1

Ensembl ID : ENSGACG00000013150
Gene Symbol: NTRK1
1 Cross references
200 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSGACG00000016216
Gene Symbol: NTRK2B
1 Cross references
210 Possible Orthologues:

Nfe2 Like Bzip Transcription Factor 2a

Ensembl ID : ENSGACG00000004470
Gene Symbol: NFE2L2A
1 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).